A Phase 1 Study of RO7616789 in People With Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Full Title

An Open-Label, Multicenter Phase I Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7616789 in Participants with Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Purpose

The purpose of this study is to find the best dose of RO7616789 to treat cancer. The people in this study have small cell lung cancer or other neuroendocrine cancers. In addition, the cancers have spread and can no longer be treated with standard therapies.

RO7616789 can help boost the immune system to fight cancer. It does this by binding to a protein on cancer cells called DLL3. It also binds to proteins on immune cells. RO7616789 may make your own cells destroy tumor cells. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have small cell lung cancer or another neuroendocrine tumor which has spread and cannot be treated with standard therapies.
• Have completed prior treatment at least 3 weeks before getting RO7616789.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please call Dr. Noura Choudhury’s office at 646-608-3762.